Polycyclic CTG-Targeting Compounds for Trinucleotide Repeat Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases caused by trinucleotide repeats, such as myotonic dystrophy, lack effectiveness and there is a need for therapeutic agents that can target and inhibit the microsatellite expansion mechanism to alleviate symptoms and prevent further progression.
Innovation Solution
Development of polycyclic compounds, including a heterocyclic core with a benzimidazole side group and optional functionalized end groups, which target expanded CTG DNA and inhibit microsatellite promoted expression, capable of crossing the blood-brain barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for trinucleotide repeat diseases, then treatment is provided, but effectiveness is lacking and symptoms are not adequately alleviated
Solution Approach 1:
The patent applies the extraction principle by designing compounds that specifically bind to and sequester toxic CUG repeat RNAs, extracting them from the cellular environment where they cause harm. The compounds contain structural elements (such as pyrimidine rings and hydrogen bonding groups) that selectively interact with the expanded CUG repeats, pulling them out of circulation and preventing their toxic effects on RNA processing and splicing regulation.
Solution Approach 2:
The patent employs the intermediary principle by introducing small molecule compounds as mediators between the toxic CUG repeats and the cellular machinery. These compounds act as intermediaries that bind to the toxic RNAs and prevent them from interfering with normal RNA binding proteins and splicing factors, thereby restoring normal RNA processing without directly modifying the toxic repeats themselves.
2Reliability
If therapeutic agents target microsatellite expansion mechanism, then RNA processing is regulated, but the agents must cross the blood-brain barrier to be effective
Solution Approach 1:
The patent applies parameter changes by carefully adjusting the physicochemical properties of the therapeutic compounds, including molecular weight, lipophilicity, and hydrogen bonding capacity. These parameter modifications enable the compounds to traverse the blood-brain barrier while maintaining their ability to bind toxic CUG repeats. The structural design includes features that optimize brain penetration without sacrificing target engagement capability.
3Reliability
If compounds are designed to rescue mis-splicing events, then therapeutic benefit is achieved, but compound structure becomes complex
Solution Approach 1:
The patent applies segmentation by dividing the therapeutic compound into distinct functional modules: a core structure for binding CUG repeats, side chains for enhancing specificity and affinity, and terminal groups for optimizing pharmacokinetic properties. This modular segmentation allows each component to contribute specifically to the overall function of rescuing mis-splicing events while keeping the total molecular complexity manageable.
Data Source
AI summary
The present disclosure provides compositions that inhibit microsatellite promoted expression of deleterious expansions by targeting expanded CTG DNA as well as methods using such compositions for use in treating or ameliorating the effects of a medical condition involving trinucleotide repeats in a subject. In embodiments, the present disclosure provides a method for treating a medical condition involving trinucleotide repeats, including a disease such as DM1, in a subject in need thereof by administering to the subject an effective amount of a modified polycyclic compound of the present disclosure. Processes for synthesizing modified polycyclic compounds that rescue mis-splicing at low nanomolar concentration with negligible toxicity are also disclosed.